Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Denileukin diftitox (DAB(389)IL-2; Ontak) is a cytotoxic fusion protein designed to target cells expressing the receptor for interleukin-2 (IL-2). It has been approved for treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor, but more recent data indicate activity in the setting of not only T-cell but also B-cell malignancies. This review will update the experience to date of denileukin diftitox in T- and B-cell malignancies.
Wong
Bryan Y
BY
Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, Nevada 89135, USA.
Gregory
Stephanie A
SA
Dang
Nam H
NH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox